Informatics In-Depth Focus 2020
The articles in this in-depth focus explain how informatics aids in the development of genomic research and outline the next steps for AI to progress in pharma.
List view / Grid view
The articles in this in-depth focus explain how informatics aids in the development of genomic research and outline the next steps for AI to progress in pharma.
This issue includes a spotlight on how genomic assays could revolutionise healthcare, a discussion on how lab automation can improve drug discovery and an analysis of whether antibodies can provide an effective coronavirus treatment. Other article topics in this issue include immuno-oncology and artificial intelligence.
A new technology called mass cytometry, or CyTOF, is providing new insights into a range of key proteins in blood cancer cells.
Using AI and deep learning, researchers have enhanced Scanning Probe Microscopy (SPM) and made their automated resource available for scientists.
Researchers have used virtual reality (VR) to control how drugs bind to their protein targets, which they say could be useful for designing new treatments.
Researchers have created a new technical resource atlas which maps the 15 distinct cell types involved in muscle repair for disease and therapy research.
Drug Target Review rounds up the latest updates on research into coronavirus treatments, focusing on virtual screening to find therapies for COVID-19.
The first drug designed using artificial intelligence (AI) has moved into its Phase I trial. Professor Andrew Hopkins of Exscientia explains how an algorithm was used to achieve this milestone.
A computational programme has been created by researchers to aid in the design of proteins for therapeutics, to predict interactions.
A new study has revealed how bacterial immune systems can be harmful for their hosts and why they are not found in all bacteria.
The newest version of the Unified Data Model (UDM) project has been released, allowing R&D scientists to access information on compound synthesis and testing.
25 February 2020 | By Bruker Daltonics
Learn about the latest software tools for Bruker Daltonic’s SPR instrumentation and explore high-throughput screening strategies enabled by their ecosystem.
A new antibiotic compound has been identified by researchers who designed a machine-learning algorithm to screen millions of molecules.
Researchers have developed an artificial neural network using deep learning to identify genes that are related to disease.
A collaboration between Elsevier and the FDA will present an algorithm for the accurate prediction of drug-induced liver injury. Drug Target Review investigates the benefits this toxicology project will bring to the drug discovery industry.